OXA-01 is an inhibitor of both mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively). OXA-01 targeted both mTORC1 and mTORC2 signaling in vitro and in vivo. OXA-01 reduced VEGF production in tumors in a manner associated with decreased vessel sprouting but little vascular regression. References: Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. PubMed PMID: 21673091.

纯度：≥98%

CAS：936889-68-8